Cullinan Oncology (CGEM) Filings

8-K

CLN-978 is the first development stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases

16 Oct 24

8-K

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

17 Sep 24

8-K

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

8 Aug 24

8-K

Submission of Matters to a Vote of Security Holders

27 Jun 24

EFFECT

Notice of effectiveness

5 Jun 24

424B3

Prospectus supplement

4 Jun 24

8-K

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

3 Jun 24

8-K

Regulation FD Disclosure

23 May 24

ARS

2023 FY

Annual report to shareholders

16 May 24

DEFA14A

Additional proxy soliciting materials

16 May 24

8-K

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

15 May 24

8-K

Departure of Directors or Certain Officers

29 Apr 24

8-K

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

16 Apr 24

S-8

Registration of securities for employees

14 Mar 24

8-K

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

14 Mar 24

8-K/A

Results of Operations and Financial Condition

8 Jan 24

8-K

Completion of Acquisition or Disposition of Assets

8 Jan 24

8-K

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

8 Nov 23

8-K

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

10 Aug 23

8-K

Departure of Directors or Certain Officers

14 Jun 23

8-K

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

25 May 23

EFFECT

Notice of effectiveness

19 May 23

CORRESP

Correspondence with SEC

16 May 23

8-K

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results

11 May 23

DEFA14A

Additional proxy soliciting materials

21 Apr 23

DEF 14A

Definitive proxy

21 Apr 23

CORRESP

Correspondence with SEC

17 Mar 23

S-8

Registration of securities for employees

9 Mar 23

S-8

Registration of securities for employees

9 Mar 23

S-3

Shelf registration

9 Mar 23

10-K

2022 FY

Annual report

9 Mar 23

SC 13G/A

VANGUARD GROUP INC

4 Nov 24

SC 13G

BlackRock, Inc.

22 Oct 24

4

Jennifer Michaelson

9 Sep 24

144

Notice of proposed sale of securities

5 Sep 24

3

Mary Thistle

9 Aug 24

4

Mary Thistle

9 Aug 24

4

Jennifer Michaelson

9 Jul 24

144

Notice of proposed sale of securities

5 Jul 24

4

Jennifer Michaelson

2 Jul 24

4

Stephen W Webster

27 Jun 24

4

Anthony Rosenberg

27 Jun 24

4

Anne-Marie Martin

27 Jun 24

4

David P. Ryan

27 Jun 24

4

Thomas Ebeling

11 Jun 24

SC 13G/A

BlackRock Inc.

7 Jun 24

4

Thomas Ebeling

23 May 24

4

David D. Meek

16 May 24

3

David D. Meek

16 May 24

4

Jennifer Michaelson

8 May 24

144

Notice of proposed sale of securities

6 May 24

4

Mary Kay Fenton

30 Apr 24

3

Mary Kay Fenton

30 Apr 24

SC 13G

Flynn James E

24 Apr 24

3

Nate Nguyen

2 Apr 24

4

Corrine Savill

23 Feb 24

4

NADIM AHMED

23 Feb 24

4

Jeffrey Trigilio

23 Feb 24

4

Jeffrey Alan Jones

23 Feb 24

4

Jennifer Michaelson

23 Feb 24

4

JACQUELYN L SUMER

23 Feb 24

SC 13G

Blue Owl Capital Holdings LP

14 Feb 24

SC 13G/A

Jovan-Embiricos Morana

14 Feb 24

SC 13G/A

BIOTECHNOLOGY VALUE FUND L P

14 Feb 24

SC 13G/A

VANGUARD GROUP INC

13 Feb 24

SC 13G

FRANKLIN RESOURCES INC

6 Feb 24

4

Corrine Savill

2 Feb 24

144

Notice of proposed sale of securities

1 Feb 24

4

Corrine Savill

30 Jan 24

SC 13G

BlackRock Inc.

29 Jan 24

144

Notice of proposed sale of securities

29 Jan 24